One in a million is not a figure of speech here: Griscelli Syndrome Type II affects roughly one in every million children, and without a bone marrow transplant most do not survive past age five. Victoria was diagnosed at two months old, received a haploidentical transplant from her father at twelve months, and returned home in July 2026 at two years old, considered cured of the hemophagocytic lymphohistiocytosis (HLH) that had compounded her already lethal underlying disorder. The transplant, performed at Nicklaus Children’s Hospital in Miami, is the first of its kind at that institution and among only a few documented cases in the United States.
The clinical complexity here deserves attention. Victoria faced two simultaneous life-threatening processes: the primary genetic defect in RAB27A-driven immune regulation that defines GS2, and a secondary HLH cascade in which the immune system turns destructive against the body’s own organs. HLH carries high acute mortality, and pharmacological options, while they exist (emapalumab gained FDA approval in 2018 for refractory primary HLH), do not address the underlying genetic defect driving recurrence. Only transplant does. The haploidentical approach, using a half-matched donor rather than waiting for a fully matched unrelated donor, is particularly consequential for ultra-rare diseases where the urgency of HLH leaves almost no time to search registries. Her father was immediately available; the transplant team at Nicklaus acted on that window.
The broader clinical signal is in the transplant design itself. Published outcomes data from a 35-patient GS2 cohort represent essentially the entire published experience with HSCT in this disease, illustrating just how thin the evidence base is. Haploidentical transplantation expands the donor pool for children who cannot wait, but it introduces graft-versus-host risk and requires sophisticated conditioning, which is why the Nicklaus team’s depth in complex pediatric transplants was the operative variable. The program describes itself as South Florida’s most experienced pediatric blood and marrow transplant provider, and this case will add a rare data point to a literature that desperately needs more of them.
The marker to watch is long-term engraftment durability. Victoria’s HLH is considered resolved, but multi-year follow-up reporting from cases like hers, added to the existing GS2 transplant literature, will be what ultimately shapes haploidentical protocols for children who present with compounded rare immune disorders and no time to spare.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
